The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.
A new study from researchers at Thomas Jefferson University delves into the details of how genetic modifiers of Huntington’s disease work.
The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntington’s disease
Replacing cells with HD in the brain could be an effective treatment strategy. Recent work shows that glia injected into mouse brains take over and oust the older cells, but for a surprising reason - because of age, not HD!
Both PTC Therapeutics and uniQure have shared updates from their respective clinical trials, testing different huntingtin-lowering approaches. We explore the data presented from both of these studies and what this means for HD family members.
Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2023
Huntington's disease research news. In plain language. Written by scientists. For the global HD community.
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2023
Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023
The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease
A new article summarizes what the Huntington's disease field has found about a type of brain cell called an astrocyte. These star-shaped cells help keep brain cells healthy and could be leveraged for developing new HD therapeutics.